Evgen Pharma Share Discussion Threads

[ny boy] 23/11/2017 11:07

The Company needs to issue a statement re the share price rise, I think it will come in the next few hours.

[werewolfie] 23/11/2017 10:47

Can't see any reason for the huge share price increase. No news

[letmepass] 23/11/2017 10:36

20k buy at 29p.. That's confidence for you

[supernumerary] 23/11/2017 10:08

Yes, I was surprised there was no comment yesterday. Timbo usually has something to say...

[shirley83] 23/11/2017 10:07

Ipo 37p.. Looks like its going for it

[euclid5] 23/11/2017 10:01

Net cash:

Evgen had £3.86m cash on the balance sheet at 31st March 2017, and with an average cash burn of ca. £300k per month, this will be sufficient to take the company through the next 12 months

hxxp://hardmanandco.com/docs/default-source/company-docs/evgen-pharma-documents/20.06.17-making-clinical-progress.pdf

[fillipe] 23/11/2017 09:37

Up 47% today at 0933hrs on substantial buying.
Full lowest ask of 25p being paid....whoops, lowest ask risen to 26p as I type.

Oddly quiet here, given the current interest in EVG which is being widely mentioned elsewhere.

f

[pdt] 07/11/2017 13:17

A couple of interesting new bits of research;

Sulforaphane reduces YAP/∆Np63α signaling to reduce cancer stem cell survival and tumor formation



and

Autophagic cell death and premature senescence: New mechanism of 5-fluorouracil and sulforaphane synergistic anticancer effect in MDA-MB-231 triple negative breast cancer cell line



From the Abstract: Sulforaphane and 5-fluorouracil have been shown to interact synergistically in the breast cancerMDA-MB-231 cell line, resulting in a significant reduction of the number of live cells compared to alone treatments

[peterm10] 03/11/2017 08:00

Oops rise that showed disappeared. Maybe my error

[peterm10] 03/11/2017 07:58

News snippet on breakfast TV about moves to speed up new drug approval. Something about simultaneous phase testing. Will try and dig out story. Could explain rise ?

[pdt] 24/10/2017 14:28

New Research on the Neuroprotective affects of Sulforaphane

Title: Nrf2-Inducers Counteract Neurodegeneration in Frataxin-Silenced Motor Neurons: Disclosing New Therapeutic Targets for Friedreich's Ataxia

From the abstract;
The in vitro treatment of the potent Nrf2 activator sulforaphane increased Nrf2 protein levels and led to the upregulation of phase II antioxidant enzymes. The neuroprotective effects were accompanied by an increase in neurites' number and extension ....Our results provide morphological and biochemical evidence to endorse a neuroprotective strategy that may have therapeutic relevance for FA. The findings of this work reinforce the crucial importance of Nrf2 in FA and provide a rationale for using Nrf2-inducers as pharmacological agents.

[pdt] 07/10/2017 09:15

New research by University of East Anglia on the effects of Sulforaphane on liver cancer.

Title: Sulforaphane exerts anti-angiogenesis effects against hepatocellular carcinoma through inhibition of STAT3/HIF-1α/VEGF signalling

From the abstract;
Collectively, these findings provide new insights into the inhibitory effect of SFN on HCC tumor angiogenesis as well as tumor growth, and indicate that SFN has potential for the prevention and treatment of HCC

[pdt] 02/10/2017 14:46

Thanks for the link. Nothing new but a good read. I liked the quote from Stephen Franklin of his hopes for SFX-01 turning breast cancer from a death sentence to a chronic condition for women where the cancer has spread. He must have knowledge of how the compassionate use programme is going when he made that quote, I think it has been active for 3 months now. Perhaps an update with results in December. All positive though and I wonder if other publications will pick up the story.

[martywidget] 02/10/2017 09:53

Here's the link, need to register to read full article:

Keep taking the broccoli, says British pharma company
October 1 2017, 12:01am, The Sunday Times

[pdt] 02/10/2017 09:32

Apparently a mention in yesterdays Sunday Times business section. I have not seen the article, anyone know what it says?

[pdt] 26/9/2017 11:31

Another good piece of research on Sulforaphane and breast cancer;

Sulforaphane-Induced Cell Cycle Arrest and Senescence are accompanied by DNA Hypomethylation and Changes in microRNA Profile in Breast Cancer Cells



A bit disappointing that the share price is drifting lower. That will not help the inevitable fund raise. Hopefully, there will be some positive news before they complete that. I have been buying on the way down but now I have probably as many as I want to hold at this stage.

[timbo003] 04/9/2017 13:13

I wondered about those options too.

Could it it a case that they are checking under the cushions of the sofa for some lost change?

They are forecast to have around £268K cash left at the end of March, but that figure depends on receiving £660K in tax credit from HMRC, so maybe it was friends and family helping out by cashing the options early (they still had a long way to run) in order to give them a bit more breathing space?

[dave444] 03/9/2017 18:05

PDT thanks!I wondered if the options exchanged for shares were people cashing in before a fund raising

[pdt] 03/9/2017 09:24

dave444 - the chances of a fundraising event are high over the next few months. They run out of cash mid 2018 and need to complete their two phase 2 trials ending late 2018. In a recent interview the CEO stated more funds would be needed. However, the amount needed is small, perhaps a £1m.

[dave444] 02/9/2017 16:32

What are the chances of a fundraising event in the next few months?

[pdt] 01/9/2017 13:41

NICE turns down AZ's Faslodex



It will be interesting if results from the Evgen trial show that SFX-01 will routinely extend progression free survival beyond six months. We know that applies to at least one participant following the compassionate use programme announcement.

Here is a quote from the above article which puts the value of such extensions in context;

"According to the data from the Phase III FALCON trial, median progression-free survival (PFS) was significantly longer with Faslodex than with anastrozole, at 16.6 months versus 13.8 months"

So potentially adding 6+ months to the above numbers. Still early days but certainly very encouraging.

[pdt] 16/8/2017 20:35

More research just published by the University of Maryland school of medicine;

"Combination Cisplatin and Sulforaphane Treatment Reduces Proliferation, Invasion and Tumor Formation in Epidermal Squamous Cell Carcinoma"

Extract From the conclusion;

"Both agents suppress tumor formation, but enhanced suppression is observed with combined treatment. Moreover, both agents reduce the number of tumor-resident cancer stem cells. SFN treatment of cultured cells or tumors increases apoptosis and p21Cip1 level, and both agents increase tumor apoptosis. We suggest that combined therapy with sulforaphane and cisplatin is efficient in suppressing tumor formation and may be a treatment option for advanced epidermal squamous cell carcinoma."



This must be encouraging for Evgen's Metastatic Breast Cancer study.

[pdt] 02/8/2017 15:56

New published research on SFX-01 and Osteoarthritis

"In conclusion, we report that SFX-01® improves bone microarchitecture in vivo, produces corresponding changes in bone cell behaviour in vitro to enhance indices of bone mechanical strength and produces greater symmetry in gait, without marked effects on cartilage lesion severity in STR/Ort osteoarthritic mice. Our findings support both osteotrophic roles and novel beneficial gait effects for SFX-01® that appear to be independent of articular cartilage lesion development in this model of spontaneous OA."



I see that the work was partly funded by Arthritis Research UK

And a quick search revealed that OA affects over 100m people in the US alone. The treatments all seem to be palliative and do not treat the problem.

[pdt] 01/8/2017 20:45

I see the RVC has put out a press release in respect of getting grant funding for a 4 year PhD study into osteoarthritis using SFX-01



Four years seems like a long time but hopefully there will be periodic updates.